The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Yahoo Finance discussed the stock recently as it posted ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Immunogen, Inc. is $8.72B. A total of 48.61 million shares were traded on the day, compared to an average of 5.74 shares.
Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, IMGN has seen 8 BUY and 5 SELL insider trades, representing the acquisition of 290,334 and the disposition of 281,882 shares. Over the last 12 months, there were 61 BUYs and 20 SELLs from insiders. Insiders purchased 4,368,089 shares during that period but sold 4,275,583.
In the most recent transaction, Enyedy Mark J sold 20,107 shares of IMGN for 29.28 per share on Feb 05. After the transaction, the CHIEF EXECUTIVE OFFICER now owns 584,397 company shares. In a previous transaction on Feb 05, Wingrove Theresa sold 12,027 shares at 29.30 per share. IMGN shares that SVP OF REGULATORY AFFAIRS owns now total 21,039.
Among the insiders who sold shares, Coen Stacy Ann disposed of 4,583 shares on Feb 05 at a per-share price of $29.30. This resulted in the SVP & CHIEF BUSINESS OFFICER holding 73,274 shares of IMGN after the transaction. In another insider transaction, Lentini Renee sold 2,631 shares at $29.30 per share on Feb 05. Company shares held by the VP & PRIN ACCTG OFFICER now total 14,723.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for IMGN in the last 3 months, the mean price target is $29.88 with high estimates of $31.26 and low estimates of $19.00. In terms of 52-week highs and lows, IMGN has a high of $31.24 and a low of $3.61.
As of this writing, IMGN has an earnings estimate of $ImmunoGen, Inc. per share for the current quarter. EPS was calculated based on a consensus of Amgen Inc. estimates, with a high estimate of $Imunon, Inc. per share and a lower estimate of $Inogen, Inc.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IMGN is Buy with a score of 3.15.